MENU

Can Delcath Systems (DCTH) Stock Reach $26?

A.I.Advisor
published price charts
A.I.Advisor
Nov 09, 2026

Can Delcath Systems (DCTH) Stock Reach $26?

Key Takeaways

  • The central target of $26 is the arithmetic mean of five verified analyst price targets reviewed for Delcath Systems, Inc. (DCTH), rounded from roughly $25.8.
  • At the latest verified close of $20.27, reaching $26 implies a substantial move of roughly 28%.
  • Individual analyst targets span a wide range from $21 to $32, with all five firms at Buy-equivalent ratings — a sign of agreement on direction but meaningful disagreement on magnitude.
  • Strongest supports include accelerating HEPZATO/CHEMOSAT commercial momentum, raised 2026 revenue guidance, positive CHOPIN trial data, and label-expansion potential.
  • Biggest risks include a very high valuation, a small-cap, single-product profile, quarter-to-quarter seasonality, and execution and clinical uncertainty.
  • For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • For automated idea generation across the market, explore Trending AI Robots.

Analyst Price Targets and Consensus View

The $26 central target is calculated from five current, attributable analyst targets. The most bullish is H.C. Wainwright at $32 (Buy, maintained November 5, 2026), while the most cautious is Canaccord Genuity at $21 (Buy, reiterated November 3, 2026). In between, Craig-Hallum holds $24 (Buy, raised from $18 on August 7, 2026), BTIG's Marie Thibault holds $25 (Buy, raised from $21 on November 9, 2026), and Clear Street holds $27 (Buy). The simple average of these five figures is about $25.8, rounded to a clean $26 for this analysis.

Every reviewed firm rates the stock a Buy, which third-party aggregators commonly summarize as a "Strong Buy" analyst consensus. However, the $21-to-$32 spread is unusually wide for a small-cap name, reflecting genuine disagreement over how quickly HEPZATO adoption and future label expansions will convert into revenue and earnings. None of these figures is a guarantee, and the mean should not be read as an official published consensus.

Current Market Position and Path Toward the Target

As of the November 9, 2026 close, Delcath Systems, Inc. (DCTH) traded at $20.27, up sharply after third-quarter results, with a market capitalization near $703 million and a 52-week range of roughly $8.12 to $20.30. Reaching $26 would require about a 28% advance — a substantial, though not extreme, move for a volatile, high-growth medical-device stock.

The path would most likely depend on sustained HEPZATO KIT revenue growth in metastatic uveal melanoma, continued expansion of U.S. treatment centers, and progress toward broader indications such as liver-dominant metastatic colorectal cancer, where the company has cleared an investigational new drug application for a Phase 2 trial. Valuation is a wildcard: with trailing EPS near zero, the stock trades on forward revenue expectations rather than earnings, making sentiment and guidance revisions unusually important.

What Could Support a Move Toward the Target

  • Commercial acceleration: Third-quarter 2026 revenue of $35.1 million beat estimates, and management raised full-year 2026 guidance to $115–$117 million, up from "at least $100 million."
  • Clinical validation: Positive CHOPIN trial results and FOCUS subgroup data support HEPZATO use in combination and sequencing, which management says is extending duration of therapy.
  • Label-expansion runway: FDA clearance of an IND for a Phase 2 colorectal cancer program and European guideline inclusion for CHEMOSAT broaden the addressable market.
  • Financial footing: Roughly $95.9 million in cash and modest leverage provide room to fund trials and commercial expansion.

What Could Prevent the Target From Being Reached

  • Rich valuation: With minimal trailing profitability, the stock is priced for sustained, execution-heavy growth; any disappointment can compress the multiple quickly.
  • Concentration risk: Revenue depends heavily on a single product and, in the U.S., primarily one indication.
  • Seasonality and lumpiness: Management has flagged fourth-quarter holiday-related step-downs in patient scheduling.
  • Competition and clinical risk: Label-expansion trials may not succeed, and competing liver-directed therapies could pressure share.

Technical Levels and Market Structure

The stock broke to a fresh 52-week high around $20.30 on November 9, 2026, clearing a prior resistance zone near $18–$18.23. That former ceiling may now act as a support level on pullbacks, with the round-number $20 area as a nearby psychological marker. The 52-week low of $8.12 sits far below, underscoring the stock's wide trading range. A sustained hold above $20 would strengthen the technical case for a move toward the $24–$26 area, while a failure back below $18 would suggest the breakout lacked conviction.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always disclose an exact timeframe. The most relevant near-term items are quarterly revenue and patient-start trends, any updates to guidance, analyst target revisions following results, and milestones in the colorectal cancer and other expansion programs. Investors should also watch treatment-center additions and any changes to the competitive or regulatory landscape.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and identify shifting trends more efficiently than manual screening alone. Because signals update with market data, they can serve as a complementary lens to traditional fundamental research rather than a replacement for it. Traders looking to streamline their daily workflow may want to review the AI Daily Buy/Sell Signals to see how the system currently assesses DCTH.

Final Assessment

The $26 central target — the mean of five Buy-rated analyst targets spanning $21 to $32 — implies a substantial, roughly 28% move from the latest close of $20.27. The strongest arguments for such a move are accelerating HEPZATO revenue, raised guidance, positive clinical data, and a widening label-expansion pipeline. The principal obstacles are a demanding valuation, concentration in a single product and indication, seasonal revenue lumpiness, and execution risk. With unanimous Buy ratings but a very wide target range, the market is clearly optimistic about direction yet uncertain about magnitude. Whether DCTH reaches $26 will hinge on continued commercial execution and credible progress toward broader indications, which investors should monitor closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

DCTH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DCTH has been loosely correlated with SGHT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DCTH jumps, then SGHT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DCTH
1D Price
Change %
DCTH100%
-2.34%
SGHT - DCTH
40%
Loosely correlated
-4.14%
PRCT - DCTH
38%
Loosely correlated
-4.08%
NVST - DCTH
38%
Loosely correlated
-1.55%
RXST - DCTH
36%
Loosely correlated
-3.04%
BWAY - DCTH
36%
Loosely correlated
-2.86%
More

Groups containing DCTH

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DCTH
1D Price
Change %
DCTH100%
-2.34%
Health Services
category (238 stocks)
7%
Poorly correlated
-2.69%
Medical/Nursing Services
category (138 stocks)
6%
Poorly correlated
-3.38%